271 related articles for article (PubMed ID: 17204351)
1. Central infusion of the melanocortin receptor antagonist agouti-related peptide (AgRP(83-132)) prevents cachexia-related symptoms induced by radiation and colon-26 tumors in mice.
Joppa MA; Gogas KR; Foster AC; Markison S
Peptides; 2007 Mar; 28(3):636-42. PubMed ID: 17204351
[TBL] [Abstract][Full Text] [Related]
2. Role of the central melanocortin system in cachexia.
Marks DL; Ling N; Cone RD
Cancer Res; 2001 Feb; 61(4):1432-8. PubMed ID: 11245447
[TBL] [Abstract][Full Text] [Related]
3. Cachexia: lessons from melanocortin antagonism.
Deboer MD; Marks DL
Trends Endocrinol Metab; 2006 Jul; 17(5):199-204. PubMed ID: 16750633
[TBL] [Abstract][Full Text] [Related]
4. Peripheral administration of a melanocortin 4-receptor inverse agonist prevents loss of lean body mass in tumor-bearing mice.
Nicholson JR; Kohler G; Schaerer F; Senn C; Weyermann P; Hofbauer KG
J Pharmacol Exp Ther; 2006 May; 317(2):771-7. PubMed ID: 16436498
[TBL] [Abstract][Full Text] [Related]
5. Effect of iguratimod and other anti-rheumatic drugs on adenocarcinoma colon 26-induced cachexia in mice.
Tanaka K; Urata N; Mikami M; Ogasawara M; Matsunaga T; Terashima N; Suzuki H
Inflamm Res; 2007 Jan; 56(1):17-23. PubMed ID: 17334666
[TBL] [Abstract][Full Text] [Related]
6. Molecular analysis of the cytokine network involved in cachexia in colon 26 adenocarcinoma-bearing mice.
Yasumoto K; Mukaida N; Harada A; Kuno K; Akiyama M; Nakashima E; Fujioka N; Mai M; Kasahara T; Fujimoto-Ouchi K
Cancer Res; 1995 Feb; 55(4):921-7. PubMed ID: 7850809
[TBL] [Abstract][Full Text] [Related]
7. Conjugated linoleic acid preserves gastrocnemius muscle mass in mice bearing the colon-26 adenocarcinoma.
Graves E; Hitt A; Pariza MW; Cook ME; McCarthy DO
Res Nurs Health; 2005 Feb; 28(1):48-55. PubMed ID: 15625711
[TBL] [Abstract][Full Text] [Related]
8. Glucocorticoid blockade does not abrogate tumor-induced cachexia.
Rivadeneira DE; Naama HA; McCarter MD; Fujita J; Evoy D; Mackrell P; Daly JM
Nutr Cancer; 1999; 35(2):202-6. PubMed ID: 10693176
[TBL] [Abstract][Full Text] [Related]
9. Comparison of animal models for head and neck cancer cachexia.
Cannon T; Couch M; Yin X; Guttridge D; Lai V; Shores C
Laryngoscope; 2007 Dec; 117(12):2152-8. PubMed ID: 17921906
[TBL] [Abstract][Full Text] [Related]
10. Chimeras of the agouti-related protein: insights into agonist and antagonist selectivity of melanocortin receptors.
Jackson PJ; Yu B; Hunrichs B; Thompson DA; Chai B; Gantz I; Millhauser GL
Peptides; 2005 Oct; 26(10):1978-87. PubMed ID: 16009463
[TBL] [Abstract][Full Text] [Related]
11. Current trends in the structure-activity relationship studies of the endogenous agouti-related protein (AGRP) melanocortin receptor antagonist.
Wilczynski AM; Joseph CG; Haskell-Luevano C
Med Res Rev; 2005 Sep; 25(5):545-56. PubMed ID: 16044415
[TBL] [Abstract][Full Text] [Related]
12. Melanocortin interventions in cachexia: how soon from bench to bedside?
DeBoer MD
Curr Opin Clin Nutr Metab Care; 2007 Jul; 10(4):457-62. PubMed ID: 17563464
[TBL] [Abstract][Full Text] [Related]
13. Erythropoietin attenuates cachectic events and decreases production of interleukin-6, a cachexia-inducing cytokine.
Kanzaki M; Soda K; Gin PT; Kai T; Konishi F; Kawakami M
Cytokine; 2005 Dec; 32(5):234-9. PubMed ID: 16338141
[TBL] [Abstract][Full Text] [Related]
14. Acute intracerebroventricular administration of either carboxyl-terminal or amino-terminal fragments of agouti-related peptide produces a long-term decrease in energy expenditure in rats.
Goto K; Inui A; Takimoto Y; Yuzuriha H; Asakawa A; Kawamura Y; Tsuji H; Takahara Y; Takeyama C; Katsuura G; Kasuga M
Int J Mol Med; 2003 Sep; 12(3):379-83. PubMed ID: 12883655
[TBL] [Abstract][Full Text] [Related]
15. Anticatabolic properties of melanocortin-4 receptor antagonists.
Madison LD; Marks DL
Curr Opin Clin Nutr Metab Care; 2006 May; 9(3):196-200. PubMed ID: 16607116
[TBL] [Abstract][Full Text] [Related]
16. Ponalrestat, an aldose reductase inhibitor, inhibits cachexia syndrome induced by colon26 adenocarcinoma in mice.
Kawamura I; Lacey E; Yamamoto N; Sakai F; Takeshita S; Inami M; Nishigaki F; Naoe Y; Tsujimoto S; Manda T; Shimomura K; Goto T
Anticancer Res; 1999; 19(5B):4105-11. PubMed ID: 10628361
[TBL] [Abstract][Full Text] [Related]
17. Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice.
Tanaka Y; Eda H; Tanaka T; Udagawa T; Ishikawa T; Horii I; Ishitsuka H; Kataoka T; Taguchi T
Cancer Res; 1990 Apr; 50(8):2290-5. PubMed ID: 2317817
[TBL] [Abstract][Full Text] [Related]
18. Central administration of peptide and small molecule MC4 receptor antagonists induce hyperphagia in mice and attenuate cytokine-induced anorexia.
Joppa MA; Ling N; Chen C; Gogas KR; Foster AC; Markison S
Peptides; 2005 Nov; 26(11):2294-301. PubMed ID: 16269355
[TBL] [Abstract][Full Text] [Related]
19. Protein metabolism in the small intestine during cancer cachexia and chemotherapy in mice.
Samuels SE; Knowles AL; Tilignac T; Debiton E; Madelmont JC; Attaix D
Cancer Res; 2000 Sep; 60(17):4968-74. PubMed ID: 10987314
[TBL] [Abstract][Full Text] [Related]
20. Role of insulin in development of cancer cachexia in nongrowing sarcoma-bearing mice: special reference to muscle wasting.
Svaninger G; Drott C; Lundholm K
J Natl Cancer Inst; 1987 May; 78(5):943-50. PubMed ID: 3553691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
